黑色素瘤靶向及免疫治疗现状与进展 |
| 张 颖，周晓鸿 |
| 昆明医科大学第二附属医院皮肤性病科，云南 昆明 650101 |
Current situation and progress of targeted therapy and immunotherapy for melanoma |
| ZHANG Ying，ZHOU Xiao-hong |
| Department of Dermatology,the Second Affi liated Hospital of Kunming Medical University,Kunming,Yunnan 650101,China |
| 摘要 |
[目的] 恶性黑色素瘤是黑色素细胞来源的高度恶性肿瘤，发病机制尚未清楚，容易远处转移、扩散，而治疗晚期患者的手段有限，预后不理想。近年来，随着肿瘤生物学和免疫学的快速发展，黑色素瘤的治疗迎来了一个崭新的阶段，靶向治疗及免疫治疗为提高晚期黑色素瘤患者的生存率带来了曙光。现就目前恶性黑色素瘤的靶向、免疫及两者联合治疗的现状及研究进展进行综述。 |
| 关键词 |
恶性黑色素瘤 ; 靶向治疗 ; 免疫治疗 ; 联合治疗 |
| Abstract： |
Malignant melanoma is a highly malignant tumor originating from melanocytes. Its pathogenesis is not yet clear, and it is easy to metasta-size and spread far away. However, the treatment methods for advanced patients are limited, and the prognosis is not ideal. In recent years, with the rapiddevelopment of tumor biology and immunology, the treatment of melanoma has ushered in a new stage, and targeted therapy and immunotherapy havebrought hope to improve the survival rate of patients with advanced melanoma. This article reviews the current situation and research progress of target-ed, immunized and combined therapy for malignant melanoma. |
| Keywords |
Malignant melanoma ; Targeted therapy ; Immunotherapy ; Combination therapy |
| 参考文献 |
［1］ Rastrelli M,Tropea S,Rossi C R,et al.Melanoma:epidemiology,riskfactors,pathogenesis,diagnosis and classification[J].Vivo,2014,28(6):1005-1011.
［2］ Melanoma Expert Committee of CSCO.Clinical practice guide-lines in oncology:Melanoma[J].Chinese Clinical Oncology,2010,15(5):385-389.
［3］ Menzies A M,Long G V.Systemic treatment for BRAF-mutantmelanoma:where do we go next?[J].Lancet Oncology,2014,15(9):e371-e381.
［4］ Si L,Kong Y,Xu X,et al.Prevalence of BRAF V600E mutation inChinese melanoma patients:Large scale analysis of BRAF and NRASmutations in a 432-case cohort[J].European Journal of Cancer,2012,48(1):94-100.
［5］ Tsai J,Lee J T,Wang W,et al.Discovery of a selective inhibitor of onco-genic B-Raf kinase with potent antimelanoma activity[J].Proceedingsof the National Academy of Sciences,2008,105(8):3041-3046.
［6］ Adina,Vultur,Jessie,et al.Targeting BRAF in advanced melanoma:afirst step toward manageable disease[J].Clinical cancer research:anoffi cial journal of the American Association for Cancer Research,2011,17(7):1658-1663.
［7］ Chapman P B,Hauschild A,Robert C,et al.Improved Survival with Ve-murafenib in Melanoma with BRAF V600E Mutation[J].New EnglandJournal of Medicine,2011,364(26):2507-2516.
［8］ Sosman J A,Kim K B,Schuchter L,et al.Survival in BRAF V600-mu-tant advanced melanoma treated with vemurafenib[J].N Engl JMed,2016,366(8):707-714.
［9］ Hauschild A,Grob J J,Demidov L V,et al.Dabrafenib in BRAF-mutat-ed metastatic melanoma:a multicentre,open-label,phase 3 randomisedcontrolled trial[J].Lancet,2012,380(9839):358-365.
［10］ Latimer N R,Abrams K R,Amonkar M M,et al.Adjusting for the Con-founding Effects of Treatment Switching--The BREAK-3 Trial:-Dabrafenib Versus Dacarbazine[J].Oncologist,2015,20(7):798-805.
［11］ Koelblinger P,Thuerigen O,Dummer R.Development of encorafenibfor BRAF-mutated advanced melanoma[J].Current Opinion in On-cology,2018,30(2):125-133.
［12］ Dummer R,Ascierto P A,Gogas H J,et al.Encorafenib plus binime-tinib versus vemurafenib or encorafenib in patients with BRAF-mu-tant melanoma(COLUMBUS):a multicentre,open-label,randomisedphase 3 trial[J].Lancet Oncol,2018,19(5):603-615.
［13］ Bradish J R,Montironi R,Lopez-Beltran A,et al.Towards personalizedtherapy for patients with malignant melanoma:Molecular insightsinto the biology of BRAF mutations[J].Future Oncology,2013,9(2):245-253.
［14］ Philip T W,Stephan D,Marcel B,et al.Prevalence of KIT Expres-sion in Human Tumors[J].Journal of Clinical Oncology,2004,22(22):4514-4522.
［15］ Kong Y,Si L,Zhu Y,et al.Large-Scale Analysis of KIT Aberrations inChinese Patients with Melanoma[J].Clinical Cancer Research,2011,17(7):1684-1691.
［16］ Guo J,Si L,Kong Y,et al.Phase II,Open-Label,Single-Arm Trial ofImatinib Mesylate in Patients With Metastatic Melanoma Harboringc-Kit Mutation or Amplifi cation[J].Journal of Clinical Oncology:Of-ficial Journal of the American Society of Clinical Oncology,2011,29(21):2904.
［17］ Pinkel D.Somatic activation of KIT in distinct subtypes of mela-noma[J].Journal of Clinical Oncology:Offi cial Journal of the Ameri-can Society of Clinical Oncology,2006,24(26):4340-4346.
［18］ Wright C,Mccormack P L.Trametinib:First Global Approval[J].Drugs,2013,73(11):1245-1254.
［19］ Flaherty K T, Ｒ obert C,Hersey P,et al.Improved survival with MEKinhibition in BRAF-mutated melanoma[J].New England Journal ofMedicine,2012,367(2):107-114.
［20］ Cui C,Mao L,Chi Z,et al.A phase Ⅱ ,randomized,double-blind,place-bo-controlled multicenter trial of Endostar in patients with metastaticmelanoma[J].Mol Ther,2013,21(7):1456-1463.
［21］ Bedikian A Y,Millward M,Pehamberger H,et al.Bcl-2 anti-sense(oblimersen sodium) plus dacarbazine in patients with advancedmelanoma:the Oblimersen Melanoma Study Group[J].J Clin Oncol,2006,24(29):4738-4745.
［22］ Flaherty K T,Infante J R,Daud A,et al.Combined BRAF and MEKinhibition in melanoma with BRAF V600 mutations[J].New EnglandJournal of Medicine,2012,367(18):1694.
［23］ Dummer R,Ascierto P A,Gogas H J,et al.Encorafenib plus binime-tinib versus vemurafenib or encorafenib in patients with BRAF -mu-tant melanoma(COLUMBUS):a multicentre,open-label,randomisedphase 3 trial[J].Lancet Oncology,2018,19(10):1315-1327.
［24］ Smith J L,Stehlin J S.Spontaneous regression of primary ma-lignant melanomas with regional metastases[J].Cancer,1965,18(11):1399-1415.
［25］ Hodi F S,O’Day S J,McDermott D F,et al.Improved survival withipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723.
［26］ Hoag H.Drug development:A chance of survival[J].Nature,2014,515(7527):118-120.
［27］ Eggermont A,Chiarionsileni V,Grob J J,et al.Adjuvant ipilimumabversus placebo after complete resection of high-risk stage III mel-anoma(EORTC 18071):a randomised,double-blind,phase 3 trial[J].Lancet Oncol,2015,16(5):522-530.
［28］ Sznol M,Kluger H M,Hodi F S.Survival and long-term follow-up ofsafety and response in patients(pts) with advanced melanoma(MEL)in a phase I trial of nivolumab(anti-PD-1;BMS-936558;ONO-4538)[J].Journal of Clinical Oncology 31(18_suppl):CRA9006.
［29］ Robert C,Long G V,Brady B.Nivolumab in previously untreatedmelanoma without BRAF mutation[J].New England Journal of Med-icine,2014,372(4):320-330.
［30］ Amm E,Blank C U,Mandala M,et al.Adjuvant Pembrolizumab ver-sus Placebo in Resected Stage III Melanoma[J].N Engl J Med,2018,378(19):1789-1801.
［31］ Tang B,Yan X,Sheng X,et al.Safety and clinical activity with an an-ti-PD-1 antibody JS001 in advanced melanoma or urologic cancerpatients[J].Journal of Hematology&Oncology,2019,12(1):7.
［32］ Johnson D B,Peng C,Sosman J A.Nivolumab in melanoma:lat-est evidence and clinical potential[J].Ther Adv Med Oncol,2015,7(2):97-106.
［33］ Krackhardt A M,Heinrich B.Progress in cancer immunotherapy[J].Mmw Fortschr Med,2017,159(14):48-53.
［34］ Daskivich T J,Belldegrun A.Words of wisdom.Re:Safety,activity,andimmune correlates of anti-PD-1 antibody in cancer[J].EuropeanUrology,2015,67(4):816-817.
［35］ Brahmer J R,Tykodi S S,Chow L,et al.Safety and activity of an-ti-PD-L1 antibody in patients with advanced cancer[J].Journal ofUrology,2012,188(6):2148-2149.
［36］ Sunshine J,Taube J M.PD-1/PD-L1 inhibitors[J].Current Opinion inPharmacology,2015(23):32-38.
［37］ Sznol M,Kluger H M,Callahan M K,et al.Survival,response du-ration,and activity by BRAF mutation(MT) status of nivolum-ab(NIVO,anti-PD-1,BMS-936558,ONO-4538) and ipilimumab(I-PI) concurrent therapy in advanced melanoma(MEL)[J].J Clin Oncol,2014,32(15):LBA9003.
［38］ Long G V,Atkinson V,Cebon J S,et al.Standard-dose pembrolizumabin combination with reduced-dose ipilimumab for patients with ad-vanced melanoma(KEYNOTE-029):an open-label,phase 1b trial[J].Lancet Oncology,2017,18(9):1202.
［39］ Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Five-Year Survival withCombined Nivolumab and Ipilimumab in Advanced Melanoma[J].New England Journal of Medicine,2019,381(16):1535-1546.
［40］ Petrella T M,Tozer R,Belanger K,et al.Interleukin-21 has activityin patients with metastatic melanoma:a phase II study[J].Journal ofClinical Oncology Offi cial Journal of the American Society of Clini-cal Oncology,2012,30(27):3396-3401.
［41］ Davar D,Ding F,Saul M,et al.High-dose interleukin-2(HD IL-2) foradvanced melanoma:a single center experience from the University ofPittsburgh Cancer Institute[J].Journal for Immunotherapy of Cancer,2017,5(1):74.
［42］ Kirkwood,J.M.A Pooled Analysis of Eastern Cooperative OncologyGroup and Intergroup Trials of Adjuvant High-Dose Interferon forMelanoma[J].Clinical Cancer Research An Official Journal of theAmerican Association for Cancer Research,2004,10(5):1670-1677.
［43］ Eggermont A,Suciu S,Santinami M,et al.Adjuvant therapy with pe-gylated interferon alfa-2b versus observation alone in resected stageIII melanoma:fi nal results of EORTC 18991,a randomised phase IIItrial[J].The Lancet,2008,372(9633):117-126.
［44］ Zong S G,Liu Z,Bartlett D L.Oncolytic Immunotherapy:Dying theRight Way is a Key to Eliciting Potent Antitumor Immunity[J].Fron-tiers in Oncology,2014(4):74.
［45］ Andtbacka R H,Kaufman H L,Collichio F,et al.Talimogene Laher-parepvec Improves Durable Response Rate in Patients With AdvancedMelanoma[J].Journal of Clinical Oncology,2015,33(25):2780-2788.
［46］ Greig S L.Talimogene Laherparepvec:First Global Approval[J].Drugs,2016,76(1):147-154.
［47］ Sarnaik A,Crago G,Liu H,et al.Assessment of immune and clinicaleffi cacy after intralesional PV-10 in injected and uninjected meta-static melanoma lesions[J].Cytokine,2014,64(1):1-10.
［48］ Au G G,Lindberg A M,Barry R D,et al.Oncolysis of vascular malig-nant human melanoma tumors by Coxsackievirus A21[J].Internation-al Journal of Oncology,2005,26(6):1471.
［49］ Dharmadhikari N,Mehnert J M,Kaufman H L.Oncolytic virus immu-notherapy for melanoma[J].Current Treatment Options in Oncolo-gy,2015,16(3):1-15.
|
| 全文稿件 |
黑色素瘤靶向及免疫治疗现状与进展.pdf (1331KB)
|
|
阅读: 248
下载: 280
上传: 2021-09-30 20:18:25
页面: 475
|
|
